You are here

Perjeta

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

Pharmaceutical Business Review

HER2+ breast cancer

Flag link:

SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis

SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis

Fierce Pharma

Flag link:

As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

Pharmaforum

HER2-positive breast cancer

Flag link:

Roche snags another Perjeta combo nod, but will 'weak' data limit its use?

Roche snags another Perjeta combo nod, but will 'weak' data limit its use?

Fierce Pharma

Flag link:

Drug developers face increasingly risky tightrope walk between top-line results and hard data

Drug developers face increasingly risky tightrope walk between top-line results and hard data

Endpoints

drug development

clinical trials

late stage data

Flag link:

4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't

4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't

Motley Fool

HER-2 postive breast cancer

multiple sclerosis

Flag link:

Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug

Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug

Endpoints

Flag link:

Roche shares spike as PhIII breast cancer combo with Perjeta scores a success, Puma takes a beating

Roche shares spike as PhIII breast cancer combo with Perjeta scores a success, Puma takes a beating

Endpoints

clinical trials

Flag link:

Roche Has Aphinity For Perjeta Trial Success, But Not Puma

Roche Has Aphinity For Perjeta Trial Success, But Not Puma

Seeking Alpha

Puma Biotechnology

Flag link:

A Look at Roche’s Potential Revenue Drivers

A Look at Roche’s Potential Revenue Drivers

Market Realist

Flag link:

Inside Roche’s Next Oncology Portfolio Drivers

Inside Roche’s Next Oncology Portfolio Drivers

Yahoo/Market Realist

T-DM1. breast cancer

Flag link:

Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar

Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar

Fierce Pharma Marketing

Flag link:

Roche's Perjeta increases survival in late-stage breast cancer study

Roche's Perjeta increases survival in late-stage breast cancer study

First Word Pharma

Flag link:

Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Fierce Pharma

Flag link:

PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative

PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative

Seeking Alpha

Lucentis Xolair

Flag link:

PDL Biopharma says it settled Roche royalty fight

PDL Biopharma says it settled Roche royalty fight

Yahoo/AP

Flag link:

FDA Approval Of Roche Cancer Drug Signals A New Paradigm

FDA Approval Of Roche Cancer Drug Signals A New Paradigm

Pharmalot

Flag link:

Roche breast cancer drug gets expanded U.S. pre-surgery approval

Roche breast cancer drug gets expanded U.S. pre-surgery approval

Reuters

Flag link:

Roche Perjeta Wins Panel Backing for Early Breast Cancer

Roche Perjeta Wins Panel Backing for Early Breast Cancer

Bloomberg

advisory panels

Flag link:

FDA scientists back accelerated approval for Roche drug to treat early-stage breast cancer

FDA scientists back accelerated approval for Roche drug to treat early-stage breast cancer

Washington Post, DC

Flag link:

Pages